Singapore, July 21 -- US-headquartered NKGen Biotech, Inc.a clinical-stage biotechnology company focused on the development and commercialisation of innovative autologous and allogeneic natural killer (NK) cell therapeutics, and Japan-based HekaBio K.K., have announced a strategic partnership to accelerate the regulatory, manufacturing and commercial development of NKGen's autologous NK cell therapy, troculeucel, in Japan following HekaBio's recently announced investment in common equity of NKGen.

HekaBio will lead all clinical trials in Japan and oversee all regulatory activities with Japan's Pharmaceuticals and Medical Devices Agency for pre-market approval of troculeucel in several neurodegenerative disease indications, including Alzh...